Drugs / In vivo CAR-T drug targeting CD20 based on mRNA-LNP
In vivo CAR-T drug targeting CD20 based on mRNA-LNP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07362602 | Jan 2026 → Dec 2027 expected | hematopoietic and lymphoid cell neoplasm | The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | In vivo CAR-T drug targeting CD20 based on mRNA-LNP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07362602 ↗ |
| Action | Deplete | “It has shown efficient B-cell clearance activity” NCT07362602 ↗ |
| Modality | Messenger RNA (mRNA) | “This experimental drug is a CD20 based messenger ribonucleic acid (mRNA) therapeutic drug, which is an injection formed by loading mRNA onto lipid nanoparticles (LNP).” NCT07362602 ↗ |